Solid Lipid Nanoparticles Could Be Used In Gene Therapy

Solid Lipid Nanoparticles Could Be Used In Gene Therapy
ScienceDaily (May 19, 2009) — Gene therapy offers hope in treating diseases such as cystic fibrosis and disorders of the retina, as well as with more common illnesses such as AIDS, cancer and neurodegenerative diseases (for example, Parkinson’s or Alzheimer’s). Now, a researcher in Spain has come up with a new approach that uses solid lipid nanoparticles to deliver therapeutic genes.
See also:
Health & Medicine
Gene Therapy
Genes
Immune System
Mind & Brain
Parkinson's
Alzheimer's
Behavior
Reference
Gene therapy
Introduction to genetics
Hormone
Tumor suppressor gene
The author of the PhD is Ms Ana del Pozo Rodríguez (Vitoria, 1980), a pharmacy graduate, who defended her thesis entitled "Development of solid lipid nanoparticles as systems for and administration in genic therapy."*
Administration of genes
Ms del Pozo’s thesis describes the development, characterisation and optimisation of a system of administration of genes based on solid lipid nanoparticles (SLNs). These particles, more or less the size of one micron and with a positive surface charge, are capable of transporting genes to the interior of the cells and enable the transport of nucleic acids — ADN or ARN — in order to be used in gene therapy. These therapies can be employed as a therapeutic tool to cure illnesses that currently only have a palliative treatment of symptoms.
The researcher studied factors related to the composition of nanoparticles that affect the capacity of transporting genes to different cells, investigating the behaviour of the particles within the cells through various microscopic techniques.
Optimisation with a peptide
In order to optimise the functioning of SLNs, these were combined with a peptide that enhances the entry of the genes into the cells — peptides are organic compounds that are found in most living tissues, and they have multiples biological functions. It is this part of the work that is being undertaken in collaboration with the IRB Group from Barcelona.
Work has also been carried out in order to improve the stability of the nanoparticles and, finally the capacity of the SNLs for transporting the genes evaluated. To this end, both in vitro and in vivo trials were undertaken — the latter through intravenous administration in mice.
Without effects for immunity
Therapies based on transporting genes to the interior of cells – using viruses – already exist. This technique is based on the natural capacity of viruses to penetrate the nucleus of a cell and so take the DNA or RNA there; however, the method can affect immunity. This is why it is necessary to develop particles with the same capacity for penetrating cells but without the side-effects on cell immunity.
*The directors of the PhD were Ms Alicia Rodríguez Gascón and Ms María Ángeles Solinís Aspiazu from the Department of Pharmacy and Food Sciences at the Pharmacy Faculty of the University of the Basque Country (UPV/EHU). In undertaking the research, the author of the thesis worked with the Ernest Giralt team at the Institut de Reserca Biomèdica in Barcelona (IRB Barcelona). Ms del Pozo Rodríguez is currently working as a researcher for CIBER-BNN at the Pharmacy and Pharmaceutical Technological Laboratory at the Pharmacy Faculty of the UPV/EHU.
Adapted from materials provided by Basque Research.
Email or share this story:
addthis_pub = 'sciencedaily';


Need to cite this story in your essay, paper, or report? Use one of the following formats:
APA MLA
Basque Research (2009, May 19). Solid Lipid Nanoparticles Could Be Used In Gene Therapy. ScienceDaily. Retrieved May 22, 2009, from http://www.sciencedaily.com­ /releases/2009/05/090518103225.htm
enlarge
Ana del Pozo Rodríguez, the PhD thesis author. (Credit: Ana del Pozo Rodríguez)
Ads by Google
Advertise here
Alzheimer'sSubscribe To Expert Clinical Information On Alzheimer's Diseasewww.UpToDate.com/Patients
Alzheimer's SymptomsLearn the 10 warning signs. See Alzheimer's Association checklist.www.alz.org/10signs
Alzheimer's Disease?A Clinical Trial Aimed At Slowing The Progression of Alzheimer'swww.ICARAstudy.com
Parkinson's Disease CMEFree CME with Case Study and Slides From Experts in Movement Disorderswww.ParkinsonsDiseaseCME.com
Powerful Immune SupportThe Original Del-Immune V Probiotic-based, recommended by MDsdelimmune.com
Related Stories
Targeted Nanoparticles Incorporating SiRNA Offer Promise For Cancer Treatment (May 21, 2007) — The use of targeted nanoparticles offers promising techniques for cancer treatment. Researchers have been using small interfering RNA (siRNA), sometimes known as silencing RNA, to "silence" specific ... > read more
Moving Gene Therapy Forward With Mobile DNA (May 9, 2009) — Researchers have developed a new non-viral gene technology approach. This approach overcomes side-effects associated with the current viral vectors, such as inflammation or the development of cancer. ... > read more
Safer Gene Therapy? Hope For Parkinson's, Alzheimer's, and MS (Oct. 27, 2007) — It is possible to sustain therapeutic gene expression in the central nervous system for up to a year, even in the presence of an anti-viral immune response mechanism that is normally present in ... > read more
Dual Gene Therapy Suppresses Lung Cancer In Preclinical Test (Jan. 15, 2007) — Combination gene therapy delivered in lipid-based nanoparticles drastically reduces the number and size of human non-small cell lung cancer tumors in mice, researchers at The University of Texas M. ... > read more
Clearer Day For Gene Therapy: New Vector Carries Big Genes Linked To Inherited Blindness (Apr. 19, 2008) — For some inherited diseases, one barrier to successful gene therapy is that a commonly used vector (package into which the curative gene is placed) cannot accommodate the large size of the curative ... > read more